The Pharmaceutical Market: India
Market Research Report

The Pharmaceutical Market: India Market Research Report

THE PHARMACEUTICAL MARKET: INDIA - REVIEW

The Indian pharmaceutical market is highly competitive and remains dominated by low-priced, domestically-produced generics. Despite having the second largest population in the world and a growing middle class with high healthcare expectations, India accounts for less than 2% of the world pharmaceutical market in value terms. In one of the world's better performing economies, spending on pharmaceuticals accounts for less than 1% of GDP and average per capita spending remains one of the lowest levels in the region.

India's biopharmaceutical sector is currently experiencing double digit growth and this is expected to continue, driven by the vaccines market. Growth drivers include education and increased awareness of disease prevention, increases in disposable income and government participation in immunisation programmes. Continued growth is also expected in the diagnostic and therapeutic segments, including cancer and diabetes. India is already known as the diabetes capital of the world and the number of diabetes patients in India is expected to grow to 70 million by 2025. Cancer therapies are also lucrative for many Indian companies due to high unmet need, increased awareness and the comparative affordability of domestically produced drugs.

The Indian pharmaceutical industry is responsible for around 10% of world pharmaceutical production. Over the last few years, a number of Indian pharmaceutical companies have been targeted for foreign acquisition. Concerns have been raised that this trend could adversely affect generic drug prices in India. The Ministry of Health wants safeguards built into the Foreign Direct Investment process amid fears that continued foreign acquisitions will adversely affect the domestic industry and push prices up, thereby potentially undermining the government's efforts to make generic drugs affordable. This could lead to essential medicines becoming more expensive and adversely affecting public health programmes.

The need to maintain low prices for essential medicines has been addressed in the government's draft National Pharmaceutical Pricing Policy (NPPP), released in 2011. The proposed NPPP focuses on the National List of Essential Medicines (NLEM), which is periodically revised. The headline major change is a move from the principle of cost-based pricing to a market-based pricing model. The Department of Pharmaceuticals argues that market-based pricing would result in more transparent and fair pricing, as well as increasing competition in the marketplace. Price regulation will encompass all drugs listed in the NLEM, as well as formulations containing combinations of drugs listed in the NLEM; this will include combinations comprising listed drugs and unlisted drugs. If the NPPP is implemented, around 60% of the drugs currently available in India will come under price control.

ENHANCED STRATEGIC INTELLIGENCE

Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

• Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
• Specialised intelligence on OTCs, generics, biologics and biosimilars.
• Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
• A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
• The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.

Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

• Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
• Specialised intelligence on OTCs, generics, biologics and biosimilars.
• Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
• A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
• The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

• EXECUTIVE SUMMARY
  • Snapshot: Strategic Espicom Analysis
  • Snapshot: Key Data Projections
• MACROENVIRONMENT
• POLITICAL
• ECONOMIC
  • Projections
  • LEGAL
  • Background to Pharmaceutical Patents
  • Mashelkar Committee Report, December 2006
  • The Patents (Amendments) Bill, 2005
  • Compulsory Licensing
  • Pre- & Post-Grant Opposition
  • Mailbox Applications
  • Other Issues
  • The Patents (Amendment) Rules, 2006
  • Previous Patents Act Amendments and Exclusive Marketing Rights
  • Challenges and Patent Decisions in the Indian High Courts
  • Novartis Once Again Challenges the Indian Patents Act
  • Bayer's Nexavar Patent Challenged by Compulsory Licence Application
  • US Special 301 Report - India Remains on Priority Watch List
• DEMOGRAPHIC
  • Population
  • Demographic Indicators
  • Births
  • Deaths
  • Infant Mortality
  • Life Expectancy at Birth
• EPIDEMIOLOGY
• DISEASE BURDEN
  • Leading Causes of Mortality
• DISEASE PREVALENCE
  • Communicable Diseases
  • HIV/AIDS
  • Leprosy
  • Tuberculosis
  • Vector Borne Diseases
  • Non-Communicable Diseases
  • Blindness
  • Cancer
  • Diabetes, Cardiovascular Disease and Stroke
  • National Rural Health Mission
• HEALTHCARE - ACCOMPANYING HEALTH STATISTICS
• ORGANISATION
  • Public Sector
  • Department of Health and Family Welfare
  • Department of AYUSH
  • Private Sector
  • Health Insurance
• EXPENDITURE
  • Projections
  • Latest Figures
• INFRASTRUCTURE
  • Hospital Infrastructure
  • Private Hospitals and Clinics
  • Apollo Hospitals Group
  • Fortis Healthcare
  • Max Healthcare
  • Wockhardt Hospitals
  • Other Commercial Providers
  • Ambulatory Infrastructure
  • Primary Care
  • First Aid and Disaster Relief
  • Healthcare for the Underprivileged, Scheduled Castes and Scheduled Tribes
• WORKFORCE
  • Projections
  • Latest Figures
• REGULATORY AFFAIRS
• NATIONAL AUTHORITY
• REGULATORY DEVELOPMENTS
  • New Drug Advisory Committees
• MARKETING REGISTRATION
  • DGCI Set to Co-ordinate Drug Approvals
• PROMOTION
• PRICING
  • Drugs (Prices Control) Amendment Order and Second Amendment Order, 2006
  • Draft National Pharmaceuticals Pricing Policy, 2011
• DISTRIBUTION CHANNELS
  • Medical Stores Organisation
  • Pharmacy Chains
  • Apollo Pharmacy
  • Guardian Pharmacy
  • Religare Wellness
  • 98.4
• MARKET ANALYSIS
  • SIZE
  • Projections
  • Historical Figures
  • Current Structure
• PRODUCT DEVELOPMENT
  • Traditional Indian Medicines
• MANUFACTURING
  • TRADE
  • Exports
  • Imports
  • Balance of Trade
• COMPETITION
  • Foreign Direct Investment in the Pharmaceutical Industry under Review
• TRADE ASSOCIATIONS
• TRADE FAIRS
  • Bangalore Bio 2012
  • India Chem 2012
  • Pharma World EXPO
• COMPANY INTELLIGENCE
  • Foreign Private Producers
  • Abbott
  • Actavis
  • Bayer Healthcare
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Mylan
  • Pfizer India
  • Reckitt Benkiser
  • Sanofi
  • Local Private Producers
  • Alembic Ltd
  • Aurobindo Pharma
  • Cipla Ltd
  • Claris Lifesciences
  • Dr. Reddy's Laboratories Ltd
  • Glenmark Pharmaceuticals
  • Jubilant Life Sciences
  • Lupin Limited
  • Natco Pharma
  • Orchid Chemicals & Pharmaceuticals Ltd
  • Piramal Healthcare
  • Ranbaxy Laboratories
  • Strides Arcolab
  • Sun Pharma
  • Torrent Pharmaceuticals
  • Wockhardt Ltd
  • Zydus Cadila
• COMPETITIVE STRATEGIES
  • Recent Acquisitions & Divestitures
  • Agreements
• BIOLOGICS & BIOSIMILARS
• COMPETITION
  • Company Intelligence
  • Avesthagen
  • BCG Vaccine Laboratory, Chennai
  • Biocon
  • Cipla
  • Claris Lifesciences
  • Dr Reddy's
  • Glenmark Pharmaceuticals
  • Lupin
  • Panacea Biotec
  • Ranbaxy/Daiichi Sankyo
  • Wockhardt
  • Zydus Cadila
• COMPETITIVE STRATEGIES
• CONCLUSIONS: OPPORTUNITIES & CHALLENGES
  • Strategic Espicom Analysis
• MACROENVIRONMENT
• EPIDEMIOLOGY
• HEALTHCARE
• REGULATORY AFFAIRS
• PRICING & REIMBURSEMENT
• DISTRIBUTION CHANNELS
  • MARKET
• COMPETITION
• OTC PHARMACEUTICALS
• GENERICS
• BIOLOGICS & BIOSIMILARS
  • Radar & SWOT Analysis
• DIRECTORY
• GOVERNMENT ORGANISATIONS
• PHARMACEUTICAL COMPANIES
• TRADE ASSOCIATIONS
• List of tabLes
  • Espicom Analysis of the Pharmaceutical Market, 2012
  • Key Data Projections, 2011-2016
  • Political Landscape, 2012
  • Regional Ranking of Projected Economies, 2016
  • Projected Economy, 2011-2016
  • Regional Ranking of Projected Demographics, 2016
  • Projected Demographics, 2011-2016
  • Summary of Demographic Data
  • Demographic Indicators, 2000-2009
  • Reported Incidence of Communicable Diseases, 2005-2009
  • Reported Incidence of Vaccine Preventable Diseases, 2008-2010
  • Regional Ranking of Projected Health Expenditure, 2016
  • Projected Health Expenditure, 2011-2016
  • Health Expenditure, 2010
  • Regional Ranking of Projected Physicians, 2016
  • Projected Physicians, 2011-2016
  • Physicians Registered with State Medical Councils, 2007-2009
  • Regional Ranking of Projected Pharmaceutical Markets, 2016
  • Projected Pharmaceutical Market at Retail Prices, 2011-2016
  • Historical Pharmaceutical Market at Retail Prices, 1995-2010 (US$ Milllion)
  • Pharmaceutical Exports by Category, 1995-2010 (US$000s)
  • Pharmaceutical Exports by Country/Region, 2010 (US$000s)
  • Pharmaceutical Imports by Category, 1995-2010 (US$000s)
  • Imports of Raw Materials by Country/Region, 2010 (US$000s)
  • Imports of Antisera & Vaccines by Country/Region, 2010 (US$000s)
  • Imports of Medicaments by Country/Region, 2010 (US$000s)
  • Balance of Pharmaceutical Trade, 1995-2010 (US$000s)
  • Foreign Acquisitions of Indian Pharmaceutical Companies, 2007-2011
  • Alembic: Financial Results, 2007-2011
  • Alembic: Manufacturing Facilities
  • Aurobindo Pharma: Financial Results, 2007-2011
  • Aurobindo Pharma: Manufacturing Facilities
  • Cipla: Financial Results, 2007-2011
  • Cipla: Manufacturing Facilities
  • Dr. Reddy's: Financial Summary, 2007-2011
  • Dr. Reddy's: Manufacturing Facilities
  • Glenmark: Financial Results, 2007-2011
  • Glenmark: Manufacturing Facilities
  • Jubilant Life Sciences: Financial Results, 2010-2011
  • Lupin: Financial Results, 2007-2011
  • Lupin: Manufacturing Facilities
  • Natco Pharma Financial Results, 2007-2011
  • Orchid: Financial Results, 2007-2011
  • Orchid's Top-10 Brands
  • Orchid: Manufacturing Facilities
  • Piramal Healthcare: Financial Results, 2007-2011
  • Piramal Healthcare: Manufacturing Facilities
  • Ranbaxy: Financial Results, 2006-2010
  • Ranbaxy: Manufacturing Facilities
  • Strides: Financial Results, 2006-2010
  • Sun Pharma: Financial Results, 2007-2011
  • Sun Pharma: Manufacturing Facilities
  • Torrent Pharma: Financial Results, 2007-2017
  • Wockhardt: Financial Results, 2006-2011
  • Wockhardt Manufacturing Facilities
  • Zydus Cadila: Financial Results, 2007-2011
  • Zydus Cadila: Manufacturing Facilities
  • Biocon: Financial Results, 2007-2011
  • Panacea Biotec: Financial Results, 2007-2011
  • Espicom Analysis of the Pharmaceutical Market, 2012
  • SWOT Analysis of the Pharmaceutical Market, 2012
• List of Charts
  • Population by Age Group (%)
  • Regional Comparison of Top 5 Projected Pharmaceutical Markets at Retail Prices, 2016
  • Regional Comparison of Projected Pharmaceutical Market Share, 2016
  • Historical Pharmaceutical Market at Retail Prices, 1995-2010
  • Pharmaceutical Exports, 1995-2010 (US$ Millions)
  • Pharmaceutical Imports, 1995-2010 (US$ Millions)
  • Pharmaceutical Imports by Country/Region, 2010 (%)
  • Balance of Pharmaceutical Trade, 1995-2010 (US$ Millions)
  • Radar Graph of the Pharmaceutical Market, 2012